RAMM Pharma

RAMM Pharma Operating Expenses

The Total Operating Expenses of RAMM Pharma (RAMM.CN) as of Oct 25, 2026 is 4.58 M CAD. In the previous year, Total Operating Expenses was 7.30 M CAD — a change of -37.33% (lower).

Operating Expenses

4.58 MCAD

YoY

-37.33%

Last updated:

Total Operating Expenses of RAMM Pharma is 2025 4.58 M CAD. Total Operating Expenses of RAMM Pharma was 2024 7.30 M CAD. It decreases by -37.33% lower compared to the previous year.

The RAMM Pharma Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
1.89 M CAD
Jan 1, 2019
6.31 M CAD
Jan 1, 2020
8.30 M CAD
Jan 1, 2021
5.69 M CAD
Jan 1, 2022
7.23 M CAD
Jan 1, 2023
6.06 M CAD
Jan 1, 2024
7.30 M CAD
Jan 1, 2025
4.58 M CAD
The RAMM Pharma Operating Expenses history
YEAROperating ExpensesYoY
4.58 MCAD-37.33%
7.30 MCAD+20.50%
6.06 MCAD-16.23%
7.23 MCAD+27.04%
5.69 MCAD-31.42%
8.30 MCAD+31.56%
6.31 MCAD+233.52%
1.89 MCAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

Total Operating Expenses of RAMM Pharma is 4.58 M CAD in 2025.

Total Operating Expenses of RAMM Pharma changed from 7.30 M CAD to 4.58 M CAD, representing a -37.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's RAMM Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — RAMM Pharma

All Key Metrics — RAMM Pharma